Company's once-daily oral quinolone antimicrobial drug lomefloxacin will be subject of a March 31 joint meeting of FDA's Anti-Infective and Dermatologic Drugs Advisory Committees. "Recent reports of phototoxicity thought to be associated with the use of lomefloxacin" and a recent Roche-sponsored animal photocarcinogenicity study in which Maxaquin "appears to act as a dermal tumor promoter" will be discussed as to their relevance to humans, regulatory options for the drug and options for information dissemination. Maxaquin was approved Feb. 21, 1992 ("The Pink Sheet" March 2, 1992, T&G-1). Meeting begins at 8:30 a.m. at the Holiday Inn, Silver Spring, Md.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth